Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2038 vs SL BPN/NX in Opioid Use Disorder
NCT02651584Phase 3Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Braeburn Pharmaceuticals. Started Dec 2015; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02651584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651584.